Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer

Introduction Trastuzumab is a monoclonal antibody which could induce the activation of a humoral immune response generating anti-drug antibodies (ADAs). Such response depends of the protein nature and the route of administration (intravenous or subcutaneous). The formation of these antibodies could...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2021-08, Vol.27 (6), p.1354-1356
Main Authors: Padrón, Ivette Mourani, García, Jonathan González, Díaz, Ruth Ramos, Lenza, Isaac Ceballos, Nicolás, Fernando Gutiérrez
Format: Article
Language:English
Subjects:
Antibodies
Antigen-antibody complexes
Breast cancer
Enzyme-linked immunosorbent assay
ErbB-2 protein
Immune response (humoral)
Immunogenicity
Intravenous administration
Metastases
Metastasis
Monoclonal antibodies
Patients
Targeted cancer therapy
Trastuzumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Trastuzumab is a monoclonal antibody which could induce the activation of a humoral immune response generating anti-drug antibodies (ADAs). Such response depends of the protein nature and the route of administration (intravenous or subcutaneous). The formation of these antibodies could block the action of trastuzumab (ADA-Tras) and forming immune complexes which decrease its efficacy, so it would be interesting to determine the presence of ADA-Tras in patients treated with trastuzumab. Material and methods The blood samples were centrifuged to separate the plasma. The presence of ADA-Tras in plasma was determined using an ELISA-type automated immunoassay. Results Fifty-one women with non-metastatic HER2-positive breast cancer treated with trastuzumab were included. Two groups were studied: patients treated intravenously and subcutaneously. In neither case was there any presence of ADA-Tras. Discussion This study may be the first ever conducted under usual clinical practice conditions to detect the presence of ADA-Tras in patients with non-metastatic HER2-positive breast cancer. We have wanted to show the antibodies anti-trastuzumab determination as a possible tool that would enable comparison of potential differences in immunogenic behavior between trastuzumab and its biosimilars.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155220953873